Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MTAP | Q13126 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23456071 | 0.85 | AGTR2 (0.38) | BCHEACHEAGTR2FFAR4 | |
| SCHEMBL23456072 | 0.85 | AGTR2 (0.38) | BCHEACHEAGTR2FFAR4 | |
| SCHEMBL23456023 | 0.83 | CHRNA7 (0.44) | — | |
| SCHEMBL23456025 | 0.83 | CHRNA7 (0.44) | — | |
| SCHEMBL783646 | 0.81 | TAAR1 (0.37) | BCHEACHEAGTR2TAAR1PDE4D | |
| SCHEMBL14722152 | 0.80 | BCHE (0.49) | BCHEACHEAGTR2TAAR1PDE4D | |
| SCHEMBL22241748 | 0.80 | BCHE (0.49) | BCHEACHEAGTR2TAAR1PDE4D | |
| SCHEMBL14719887 | 0.80 | BCHE (0.49) | BCHEACHEAGTR2TAAR1PDE4D | |
| SCHEMBL23313010 | 0.80 | BCHE (0.49) | BCHEACHEAGTR2TAAR1PDE4D | |
| SCHEMBL14719819 | 0.80 | BCHE (0.49) | BCHEACHEAGTR2TAAR1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-06 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| EP-3707151-B1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICALS CO (JP) | 2022-01-05 | — | — | EP | disclosed |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | BCHE 4379/4885ACHE 4013/4885AGTR2 1627/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | BCHE 4379/4885ACHE 4013/4885AGTR2 1627/4885 |
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | BCHE 4379/4885ACHE 4013/4885AGTR2 1627/4885 |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | BCHE 4379/4885ACHE 4013/4885AGTR2 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.